Introduction {#S1}
============

Haemangiomas represent the most common benign tumours in infancy, affecting 1-2% of newborns [@R01]. Although they are often confused with other vascular malformations, they demonstrate a unique course characterized by proliferation during the first year of life, and involution thereafter.

Fortunately, many haemangiomas are superficial involving only skin and subcutaneous tissue, and can be allowed to follow their self-limiting natural course, and resolve with minimal sequelae. However, approximately 10% of haemangiomas can affect the child\'s quality of life due to aesthetic reasons or cause functional impairment, which can even be life-threatening [@R02].

Airway haemangiomas in particular may lead to feeding difficulties, barking cough, stridor, respiratory distress and even acute airway obstruction. Hence, such haemangiomas usually require early and aggressive treatment; however, the treatment modalities employed so far have been associated with their own co-morbidities and potential long-term adverse effects for the developing child. In other words, the traditional management (medical or surgical) of severe or life threatening airway haemangiomas may have a serious impact on the child\'s quality of life, or be associated with severe complications.

Recently, Leaute-Lambreze et al. reported the accidental regression of an infantile haemangioma following the administration of propranolol for steroid-induced hypertrophic cardiomyopathy [@R03]. This had led other otolaryngology centres to try the same method of management in order to achieve a good clinical result with minimal complications. The first related studies, usually case reports or case series, were very encouraging claiming that a new revolutionary method of management had been discovered [@R04]^-^[@R07].

The aim of the present meta-analysis is to critically review the current evidence on the efficacy of propranolol in the management of airway haemangiomas. Adverse events and treatment failures are also explored.

Materials and Methods {#S2}
=====================

An extensive search of the literature was performed in Medline and other available database sources, establishing two main categories of outcomes:

a.  assessment of the clinical effectiveness of systematically administered propranolol in halting the progress of growing airway haemangiomas, and

b.  comparison of the clinical outcome of propranolol versus the systemic, or intralesional steroid administration as a first-line approach for the treatment of proliferating airway haemangiomas.

Using this framework of results, the retrieved studies were critically appraised according to evidence-based guidelines for the categorization of medical studies ([Tab. I](#T1){ref-type="table"}).

###### 

Levels of evidence regarding in studies that investigate the results of treatment.

  Category of evidence   Study design
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Level I                High quality randomized trial with statistically significant difference, or no statistically significant difference, but narrow confidence intervalsSystematic review of Level I randomized control trials (and study results were homogenous)
  Level II               Lesser quality randomized control trial (e.g. \< 80% follow up, no blinding, or improper randomization)Prospective comparative studySystematic review of Level II studies or Level I studies with inconsistent results
  Level III              Case control studyRetrospective comparative studySystematic review of Level III studies
  Level IV               Case series
  Level V                Expert opinion

In addition, three secondary end-points were also analysed:

a.  clinical effectiveness of propranolol in eradication of proliferating airway haemangiomas,

b.  clinical effectiveness of propranolol compared to previously utilized second-line treatments for infantile haemangiomas, and

c.  protocol for the safe administration of propranolol, and appropriate patient follow-up until complete resolution of the disease.

During the search, the keywords \"haemangioma\", \"infantile\", \"airway\", \"proliferation\", \"propranolol\", \"steroids\", and \"treatment\" were utilized. The keywords \"haemangioma\", \"airway\", and \"propranolol\" were considered primary, and were either combined to each of the other keywords individually, or used in groups of three. In addition, reference lists from the retrieved articles were manually searched. Language restrictions limited the search to English-language articles only.

The clinical effectiveness of propranolol was assessed using chi-square analysis. Chi-square was also used to determine the comparative effectiveness of propranolol vs. steroid administration. The degree of airway obstruction before and after treatment with propranolol was compared using a paired t-test. The correlation coefficient between treatment with propranolol and the change in the percentage of airway obstruction post-treatment was calculated using linear regression. Statistical importance was accepted at the level of P \< 0.05.

Results {#S3}
=======

Eighteen studies met the defined criteria and were initially included in study selection. Among these studies, one included patients with overlapping haemangiomas, frequently involving more than one anatomic site in the same patient, without, however, clear identification of the number of patients with airway haemangiomas. This study was therefore excluded from the analysis of pooled data.

Overall, one multi-centre retrospective cohort study, two prospective cohort and two retrospective studies, six caseseries, and six case reports were systematically analyzed. Two studies represented Level II, three studies Level III and 12 studies Level IV evidence ([Tab. I](#T1){ref-type="table"}).

The total number of treated patients was 61; among these 35 had exclusive airway lesions. Co-existing segmental distribution of haemangiomas was present in 11 children, cutaneous lesions in nine, deep neck/mediastinal components in four and finally PHACE S syndrome (posterior fossa malformations, haemangiomas, arterial anomalies, coarctation of the aorta/cardiac defects, eye abnormalities and sternal defects) in two of the treated children. The vast majority of patients (n = 43) received 2 mg of oral propranonolol per day divided in 2 or 3 doses; a dose of 3 mg per day was given in 10 children, whereas the administered dose was not reported in 4 cases.

Fourteen patients received propranolol as single treatment. Four patients were treated with another selective β-blocker (acebutalol), but showed similar responses, and were hence included in further analysis of treatment outcomes. The comparative effectiveness of propranolol vs. systemic steroids was documented in 35 children ([Tab. II](#T2){ref-type="table"}). Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%). The result was statistically significant (p \< 0.001). Propranolol was also used as salvage therapy in 10 children previously treated with laser, and in three children who had previously received vincristine; better results demonstrating a clear advantage for propranolol were reported in all of these patients.

###### 

Comparative effectiveness of propranololol vs. systemic steroids in the management of airway haemangiomas (raw data).

  Case   Systemic prednisolone                             Steroid effectiveness   Propranolol                                     β-blocker efficiency   Additional treatment
  ------ ------------------------------------------------- ----------------------- ----------------------------------------------- ---------------------- ----------------------
  1      High doses (details missing)                      No                      3 mg/kg/day                                     Success                No
  2      High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  3      2 mg/kg/day                                       No                      2 mg/kg/day[^≠^](#T2FN1){ref-type="table-fn"}   Success                No
  4      3 mg/kg/day                                       No                      3 mg/kg/day                                     Success                No
  5      2 mg/kg/day                                       No                      3 mg/kg/day                                     Success                No
  6      2 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  7      2 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  8      2 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  9      2 mg/kg/day                                       No                      3 mg/kg/day                                     Success                No
  10     1 mg/kg/day                                       No                      8 mg/kg/day[^†^](#T2FN2){ref-type="table-fn"}   Success                No
  11     1 mg/kg/day                                       No                      8 mg/kg/day[^†^](#T2FN2){ref-type="table-fn"}   Success                No
  12     1.5 mg/kg/day                                     No                      3 mg/kg/day                                     Success                No
  13     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  14     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  15     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  16     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  17     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  18     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  19     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  20     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  21     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  22     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  23     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  24     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  25     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  26     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  27     0.1 mg/kg/day[^‡^](#T2FN3){ref-type="table-fn"}   No                      2 mg/kg/day                                     Success                No
  28     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  29     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  30     3 mg/kg/day                                       No                      2 mg/kg/day                                     Success                No
  31     3 mg/kg/day                                       Yes                     2 mg/kg/day                                     Failure                No
  32     High doses (details missing)                      No                      2 mg/kg/day                                     Success                No
  33     100 μg/kg/day[^§^](#T2FN4){ref-type="table-fn"}   No                      2 mg/kg/day                                     Success                No
  34     High doses (details missing)                      No                      Details missing                                 Success                No
  35     High doses (details missing)                      Yes                     Details missing                                 Failure                No

the patient was initially treated with propranolol, but later received acebutalol, due to asthmatic attack

the patient received acebutalol

the patient received betamethasone

the patient received dexamethasone

Drawing on the degree of improvement of airway obstruction, this was clearly documented as a respective percentage in 21 patients. The mean obstruction before the administration of propranolol was 72%, and after intervention was 20%. The result proved statistically significant (p \< 0.001).

The mean referral age for children with airway haemangiomas was 2.4 months (range 0.7-8 months), and the mean starting age of propranolol treatment 5.1 months (range 0.75-22 months). Treated children were followed up for a mean of 8.4 months. Four children from our study population failed to respond to propranolol treatment (6.5%), and in seven the haemangioma relapsed after discontinuation of treatment (11.5%).

Discussion {#S4}
==========

Epidemiology-Pathophysiology {#S4a}
----------------------------

Infantile haemangiomas seem to affect 4-10% of Caucasian infants, with a female to male ratio of 2.5-4:1 [@R08]^-^[@R10]. They have also been associated with prematurity, low birth weight and multiple pregnancies [@R11]^-^[@R13]. Sixty per cent of haemangiomas represent single lesions, and 80% are found in the head and neck area [@R08] [@R14]. Airway haemangiomas can involve any site from the nares to the tracheobronchial tree. However, they are most commonly seen in the subglottis, and account for approximately 1.5% of congenital laryngeal anomalies [@R15]. The natural history of haemangiomas in the subglottis may be accompanied by an alarming mortality rate of around 50% if left untreated [@R16] [@R17]. Indeed, approximately two-thirds of these haemangiomas present with 70% or worse airway narrowing [@R18] [@R19]. Histologically, infantile haemangiomas are composed of a complex mixture of clonal epithelial cells associated with pericytes, fibroblasts, dendritic and mast cells [@R06] [@R08]^-^[@R10] [@R20] [@R21]. Although theories regarding their origin involve potential somatic endothelial mutations, intrinsic defects, extrinsic factors (i.e. tocolytics) and placental derivation [@R08] [@R22] [@R23], no current hypothesis can explain all their characteristics. It has been proposed recently that the tumour may be a developmental disorder of primitive mesodermal proliferation and differentiation governed by the renin-angiotensin system [@R24] [@R25].

Haemangioma growth is controlled by pro-angiogenic factors during the proliferative phase, predominantly basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VE GF). Conversely, the involutional phase is associated with cell apoptosis resulting in tumour regression [@R06] and replacement with fibro-fatty tissue [@R26]. Immunochemistry shows persistent reactivity to the erythrocytetype glucose transporter protein isoform 1 (GL UT-1) [@R08] [@R27].

Treatment modalities-Mechanism of propranolol action {#S4b}
----------------------------------------------------

A variety of treatment modalities have been used in the management of airway haemangiomas. Although the treatment plan depends on many factors (i.e. size and extend of the lesion, social situations, clinical experience etc.), a widely accepted aim is to maintain airway patency, promote lesion regression, avoid tracheostomy and minimize therapeutic side effects until the lesions enter the natural phase of involution [@R04] [@R15]. Unfortunately, a watchful-waiting policy can only be applied in the minority of patients who do not demonstrate respiratory or feeding difficulties [@R19].

The gold standard for the treatment of symptomatic airway haemangiomas until recently has been the administration of steroids. Systemic steroids can be effective in controlling haemangioma growth in over 50% of patients [@R10] [@R28]^-^[@R30], even though subglottic lesions tend to show poorer response [@R29]. However, their side-effects are also well known; cushingoid face, insomnia, irritability, growth retardation, gastro-intestinal lesions, delayed wound healing, hirsutism, and even adrenal suppression, hypertension, or hypertrophic cardiomyopathy.

Interferon-α, on the other hand, has been widely used for the treatment of refractory haemangiomas, but is associated with significant neurotoxic effects, such as spastic diplegia and developmental delay [@R09], especially in young infants [@R18], while it may also be responsible for a variety of other sideeffects (flu-type malaise, neutropenia, elevation of liver enzymes, hypothyroidism). Vincristine therapy has also been employed in life-threatening conditions, but may cause peripheral neuropathy resulting in constipation, abdominal pain and paraesthesia, in addition to inappropriate secretion of antidiuretic hormone. In these latter cases, cyclophosphamide has also been reported to have promising results [@R31]. However, the serious side-effects related to cyclophosphamide (i.e. avascular necrosis, cardiomyopathy, pulmonary fibrosis, gonadal damage, and later malignancies [@R32]) have to be carefully considered prior to the initiation of treatment. In addition, it should not be forgotten that vincristine and cyclophosphamide are mainly anti-cancer drugs with potentially very serious side effects in the long-term, especially when given to very young children.

A number of surgical interventions have also been attempted, especially in cases that do not respond to medical therapy. Tracheostomy [@R33] can no longer be considered as first-line treatment, not only because of the relatively low risk of mortality (approximately 1%), but also for the associated morbidity (including the serious impact on the child\'s and family\'s quality of life), and the need for close postoperative tracheostomy care [@R19] [@R34]. However, in emergency cases tracheostomy may be the only immediate solution to save the child\'s life.

Intra-lesional steroids may reduce the related systematic morbidity, although their results have been variable [@R35], and they often involve prolonged intubation and stay in a paediatric ICU; the associated risks are also not considered acceptable by many authors [@R15].

Laser ablation is considered a reasonable option for localized haemangiomas not causing extreme airway narrowing. As with other modalities of treatment, the respective efficacy varies, whereas the associated risk includes high recurrence rates that may lead to multiple treatments [@R36] [@R37]. Extensive circumferential narrowing is not suitable for laser debulking, due to the risk of postoperative scarring, and the ensuing subglottic stenosis. Hence, open resection and laryngo-tracheal augmentation may be ultimately required. However, these are relatively major surgical procedures with potentially serious complications. Moreover, they demand inpatient management, intensive care units and vast related experience on behalf of the operating surgeon.

The incidental discovery that propranolol induced early regression of infantile haemangiomas during their proliferative phase by Leaute-Labreze et al, along with its low side-effect profile, attracted significant attention, and propranolol- based regimens have emerged as a new method of treatment in a growing volume of literature. However, the use of propranolol for proliferative infantile haemangiomas in the first year of life is still officially considered \"off label\".

The exact mechanism of propranolol action in infantile haemangiomas is equally unclear to their origin. Propranonol is a non-selective β-blocker inhibitor, with pure antagonistic effects. Proposed mechanisms of action include control of hypoxic stress, vasoconstriction, inhibition of angiogenesis and induction of endothelial cell apoptosis. Vasoconstriction can be visible as a change in colour, associated with palpable tissue softening, which can be observed as early as 1-3 days from treatment onset [@R08] [@R15] [@R38]. The anti-angiogenic effect of propranolol can be exercised through its anti-VE GF activity [@R03] [@R11], as well as through reduced activity of the renin-angiotensin system and reduced expression of matrix metalloproteinases (MMPs) [@R08]. The resulting growth arrest is followed by regression of the lesions through an increase in the rate of apoptosis. The latter, however, is not complete in young infants, as partial re-growth of haemangiomas has been observed after the discontinuation of propranolol administration. In addition, variability in response can be suggestive of variability in tumour composition [@R39].

Meta-analysis {#S4c}
-------------

The results of the present meta-analysis suggest that propranolol is indeed effective in the treatment of airway haemangiomas (p \< 0.001). The vast majority of children that received propranolol for airway hemangiomas showed improvement or resolution of symptoms, and normal thriving. Non-responsiveness to propranolol was only reported in four children (6.5%), whereas seven additional children relapsed following the discontinuation of treatment (11.5%). An interesting observation is that the administration of propranolol as monotherapy for airway haemangiomas in 14 infants resulted in 2 treatment failures (14.3%), but only one relapse after cessation of therapy (7.1%). Considering the respective percentages of the entire study population, this observation suggests that enhanced alert is required, when it is decided to treat infants exclusively with propranolol for airway haemangiomas, as the risk of non-responsiveness is increased. Indeed, in an area where compromise can be lethal, these patients should be monitored closely as they may require adjuvant therapy. In addition, despite the great efficiency of propranolol, recurrences of airway haemangiomas are possible after early or even late discontinuation of treatment. The cause of these relapses is equally unknown to the mechanism of propranolol action; the present metaanalysis identified a specific cause of haemangioma recurrence in only one of the 7 relapsing infants (administration of a sympathomimetic drug during cardiac surgery). It should be noted, however, that the mean follow up period of treated children identified in the present metaanalysis (8.4 months) is somewhat restrictive in assessing the above-mentioned important issues.

Unfortunately, sizing of the obstructed airway in order to quantify the exact value of improvement following the administration of propranolol, especially in cases of subglottic haemangiomas, was not reported in all studies. However, the present meta-analysis identified a subpopulation of treated children (n = 21), where such measurements had been performed during microlaryngoscopy and bronchoscopy under general anaesthesia (MLB), before and after intervention. As seen in [Figure 1](#F1){ref-type="fig"}, the percentage of obstruction had dramatically decreased following propranolol administration in most cases. The related difference was statistically significant (p \< 0.001). In addition, the correlation co-efficient between treatment with propranolol and the change in the percentage of obstruction post-treatment was found to be moderately positive (r = 0.39), and again statistically significant (p \< 0.05) ([Fig. 2](#F2){ref-type="fig"}).

![Percentage of airway obstruction before and after propranolol treatment.](0392-100X-32-213-g001){#F1}

![Scatter plot illustrating the relationship of propranolol to the result of treatment. The line of best fit shows a moderately positive correlation (r = 0.39).](0392-100X-32-213-g002){#F2}

The administration of propranolol as single-therapy is also a case-in-point, especially if we consider the relatively increased risk of non-responsiveness mentioned above. In particular, among the aforementioned 21 cases, five children had received propranolol as monotherapy. The mean obstruction before the administration of propranolol was 66%, and after intervention was 24%. Despite the small number of cases, the result was statistically significant (p = 0.01).

It should be noted that not all children show complete eradication of the haemangioma after being treated with propranolol. Indeed, only four children were reported as having no obstruction, and two additional children as having 5% of the subglottic airway obstructed. However, steroids and other medical methods of treatment do not eradicate the disease either. Therefore, symptom improvement/resolution and the ability of the infant to thrive, although subjective, can be considered the most important criteria of success. Nevertheless, if we put an arbitrary cut-off criterion of success -- 10% of the airway to be obstructed after the intervention -- then over 50% of responders can be expected to reach this significant target. The latter observation can be used for parent counselling before obtaining consent for the initiation of treatment.

In addition, propranolol was found more effective than steroids in treating airway haemangiomas (p \< 0.001). Indeed, the respective odds ratio for successful outcome for propranolol vs. steroid treatment was positive and statistically significant (p \< 0.05). In comparison to the previously considered second-line treatments for proliferating infantile haemangiomas, propranolol tended to outperform both laser treatment and vincristine, although the small number of patients treated with these modalities did not allow significant comparisons to be made. Nevertheless, when propranolol was used as salvage therapy in 10 children previously treated with laser, and in three children who had previously received vincristine, it achieved better symptom control in all.

Admittedly, the present meta-analysis did not identify any Level I studies regarding the administration of propranolol for the treatment of proliferating airway haemangiomas. The vast majority of studies were small case series, and the number of treated children was also relatively small. However, the reported results seem encouraging. In addition, the uniform nature of these results, along with the quality of the studies performed, allow us to adopt a grade C strength of recommendation regarding the effectiveness of propranolol in airway haemangiomas ([Tab. III](#T3){ref-type="table"}). However, the rather small number of patients with airway haemangiomas, who were treated solely with propranolol ([Tab. IV](#T4){ref-type="table"}), precludes us from drawing definite conclusions regarding the strength of recommendation for the effectiveness of propranolol as single-therapy for airway haemangiomas. We hope that the results of the present study will encourage further high quality studies with long term follow-up in order to clarify this important issue.

###### 

Strength of recommendation by category of evidence for guideline development [@R40].

  Strength of recommendation   Category of evidence
  ---------------------------- -----------------------------------------------------------------------------------------------------------
  A                            Directly based on category I evidence
  B                            Directly based on category II evidence or extrapolated recommendation from category I evidence
  C                            Directly based on category III evidence or extrapolated recommendation from category I or II evidence
  D                            Directly based on category IV evidence or extrapolated recommendation from category I, II or III evidence

###### 

Propranolol administration for airway haemangiomas (patient series).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                                          Study type                         Evidence level   Number of subjects with airway haemangioma   Treatment failure/relapse   Adverse effects
  ---------------------------------------------------------------- ---------------------------------- ---------------- -------------------------------------------- --------------------------- -----------------------------------------------------
  Holmes et al., 2011                                              Prospective study                  II               1                                            0                           None

  Guye et al., 2011 [@R41]                                         Case report                        IV               1                                            0                           None

  Leboulanger et al., 2010 [@R42]                                  Multicentre retrospective cohort   III              14                                           2                           

  Blanchet et al., 2010 [@R43]                                     Case series                        IV               4                                            1                           None

  Truong et al., 2010 [@R44]                                       Case series                        IV               6                                            0                           None

  Santos et al., 2010                                              Case series                        IV               6                                            1                           Asthma (n = 1)

  Rosbe et al., 2010 [@R45]                                        Case series                        IV               3                                            1                           Soft palate ulcer (N = 1)

  Canadas et al., 2010 [@R46]                                      Case report                        IV               1                                            1                           None

  [^\*^](#T4FN1){ref-type="table-fn"} Manunza et al, 2010 [@R47]   Case-series                        IV               9                                                                        Pallor (n = 1) Asthma (n = 1)

  Jepshon et al, 2009                                              Case report                        1                0                                            None                        

  Maturo and Hartnick, 2010 [@R48]                                 Case series                        IV               2                                            0                           None

  Larrier, 2010 [@R49]                                             Retrospective study                III              3                                            2                           None

  Anderson de Moreno et al,\                                       Retrospective study                III              4                                            0                           None
  2009 [@R50]                                                                                                                                                                                   

  Sans et al, 2009                                                 Prospective cohort                 II               4                                            0                           Not specified for patients With airway haemangiomas

  Buckmiller et al, 2009                                           Case report                        IV               1                                            0                           None

  Theletsane et al, 2009                                           Case report                        IV               1                                            0                           None

  Mistry and Tzifa, 2009                                           Case report                        IV               1                                            0                           None
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

authors belong to the same investigating team

Treatment regimen-Follow up algorithm {#S4d}
-------------------------------------

Propranolol, a non-selective β-blocker, was considered one of the most important contributions to clinical medicine and pharmacology of the 20^th^ century [@R08]. It is almost completely absorbed from the gastro-intestinal tract, highly protein-bound (80-95%), and there is a significant first pass metabolism and hepatic tissue binding, with up to 90% of an oral dose being eliminated. Like many drugs adapted for use in infants, there are no pharmacokinetic data in this specific population, and no prospective, controlled studies have described optimal dosing or monitored the respective side-effects in this age group [@R51].

The potential risks associated with the use of propranolol include cardio-pulmonary complications, such as bradycardia, and hypotension, especially in syndromic children (i.e. PHACES, PELVIS etc.) and neonates in the first week of life [@R48], bronchospasm in patients with atopic predisposition or underlying spastic respiratory illness [@R52], hypoglycaemia, especially in low birth weight newborns [@R09] and children with low caloric intake [@R53] or diabetes, electrolytic abnormalities (i.e. hyperkalaemia [@R52]), gastro-oesophageal reflux, somnolence/fatigue, agitated sleep, rash and resistance to the drug\'s re-introduction after early discontinuation of therapy [@R42]. These effects, however, appear minor, compared to the serious side effects of more conventional agents, such as the ones mentioned earlier. In addition, after over 40 years of extensive clinical experience with propranolol, no serious cardiovascular event has been recorded in a child on chronic β-blocker therapy [@R54]. Nevertheless, the adoption of this treatment modality by non-familiar specialties, such ENT, certainly warrants careful monitoring, close liaise with the affiliated paediatric Cardiology Department, and a treatment algorithm to minimize the potential adverse effects [@R15] [@R28] [@R39] [@R51] [@R55]. The present meta-analysis identified only four adverse effects in children receiving propranolol for the treatment of airway haemangiomas; two asthmatic attacks, which had necessitated cessation of treatment, one episode of pallor without loss of consciousness, which was attributed to a possible vagal reaction, but did not require discontinuation of treatment or dose adjustment and a soft palate ulcer, which responded to steroid treatment.

The pharmacologically optimal dosing interval for propranolol is 6 hours, although better compliance is achieved when the medication is given 2 or 3 times daily. Before starting the treatment, baseline vital signs are obtained [@R51], along with blood glucose, especially if the child has not established a routine feeding pattern [@R48]. Electrocardiogram and echocardiogram are also necessary, and if either is abnormal a cardiology review is required [@R51]. Infants with large haemangiomas and especially segmental distribution are at increased risk of high output cardiac failure, and propranolol can conceal the related tachypnoea and hyperidrosis [@R51]. Syndromic children are also evaluated with trans-cranial Doppler and/or MRI /MRA of the head and neck [@R48]. Otherwise, a CT scan of the neck with intravenous contrast gives optimal resolution of the haemangioma [@R56], without the need to intubate the infant.

Hospitalized infants receive a starting dose of 0.17 mg/kg three times daily. Vital signs and blood glucose are checked 1 hour after each dose, as this corresponds to the peak absorption time. If the first 2 doses are tolerated, the dose is doubled to 0.33 mg/kg, and after 2 more doses to 0.67 mg/ kg. For infants less than 3 months of age, slower dose escalation to avoid hypoglycaemia may be required. Frequent feeds are strongly encouraged. Parents need to be informed about the clinical signs of hypotension, bradycardia and hypoglycaemia, as for the need of dose adjustment according to the child\'s weight [@R48]. The optimal duration of treatment is not known, but it is currently believed that the child should remain on propranolol until the haemangioma enters the phase of involution, which usually happens after the first year of life. Earlier discontinuation of treatment may result in unresponsiveness to propranolol re-introduction, should the latter be required. Moreover, the lack of long-term follow up in the published studies does not allow any definite conclusions with regard to relapses, even after the beginning of the involutional phase.

If a child is unresponsive to propranolol, biopsy (taking all the necessary precautions to control a potentially persistent and life threatening bleeding) and immunohistochemical staining for GLUT-1 may be considered to confirm diagnosis [@R28] [@R44]. Finally, propranolol is gradually tapered over 2-3 weeks, and not stopped immediately, due to issues involving cardiac hypersensitivity.

Conclusions {#S5}
===========

Airway haemangiomas may require early and aggressive treatment in life-threatening cases. However, the treatment modalities employed so far have been associated with their own comorbidities and potential long-term adverse effects for the developing child. Propranolol has the potential to alter the management of proliferating haemangiomas in infancy radically. Although high-quality evidence is still not available, the results of the present study suggest that propranolol can be recommended for the treatment of airway haemangiomas, as it was found to be effective and outperformed the previously-considered gold standard methods of treatment (p \< 0.001) with fewer side-effects. Immediate treatment with propranolol should commence once a diagnosis of symptomatic airway haemangioma is confirmed and a cardiovascular assessment has taken place. Active parental monitoring is also essential to ensure treatment safety.
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